An evaluation of the use of DirectSPR images for proton planning in the RayStation treatment planning software.

An important source of uncertainty in proton therapy treatment planning is the assignment of stopping-power ratio (SPR) from CT data. A commercial product is now available that creates an SPR map directly from dual-energy CT (DECT). This paper investigates the use of this new product in proton treatment planning and compares the results to the current method of assigning SPR based on a single-energy CT (SECT). Two tissue surrogate phantoms were CT scanned using both techniques. The SPRs derived from single-energy CT and by DirectSPR™ were compared to measured values. SECT-based values agreed with measurements within 4% except for low density lung and high density bone, which differed by 13% and 8%, respectively. DirectSPR™ values were within 2% of measured values for all tissues studied. Both methods were also applied to scanned containers of three types of animal tissue, and the expected range of protons of two different energies was calculated in the treatment planning system and compared to the range measured using a multi-layer ion chamber. The average difference between range measurements and calculations based on SPR maps from dual- and single-energy CT, respectively, was 0.1 mm (0.07%) versus 2.2 mm (1.5%). Finally, a phantom was created using a layer of various tissue surrogate plugs on top of a 2D ion chamber array. Dose measurements on this array were compared to predictions using both single- and dual-energy CTs and SPR maps. While standard gamma pass rates for predictions based on DECT-derived SPR maps were slightly higher than those based on single-energy CT, the differences were generally modest for this measurement setup. This study showed that SPR maps created by the commercial product from dual-energy CT can successfully be used in RayStation to generate proton dose distributions and that these predictions agree well with measurements.

Human factor associations with safety events in radiation therapy.

BACKGROUND AND PURPOSE: Incident learning can reveal important opportunities for safety improvement, yet learning from error is challenged by a number of human factors. In this study, incident learning reports have been analyzed with the human factors analysis classification system (HFACS) to uncover predictive patterns of human contributing factors. MATERIALS AND METHODS: Sixteen hundred reports from the Safety in Radiation Oncology incident learning system were filtered for inclusion ultimately yielding 141 reports. A radiotherapy-specific error type was assigned to each event as were all reported human contributing factors. An analysis of associations between human contributing factors and error types was performed. RESULTS: Multiple associations between human factors were found. Relationships between leadership and risk were demonstrated with supervision failures. Skill-based errors (those done without much thought while performing familiar tasks) were found to pose a significant safety risk to the treatment planning process. Errors made during quality assurance (QA) activities were associated with decision-based errors which indicate lacking knowledge or skills. CONCLUSION: An application of the HFACS to incident learning reports revealed relationships between human contributing factors and radiotherapy errors. Safety improvement efforts should include supervisory influences as they affect risk and error. An association between skill-based and treatment planning errors showed a need for more mindfulness in this increasingly automated process. An association between decision and QA errors revealed a need for improved education in this area. These and other findings can be used to strategically advance safety.

Seismic reinforcement of a linac installation.

The local building requirements to secure medical equipment in seismically active areas in the United States are based on recommendations of the American Society of Civil Engineers. In our institution we have recently acquired new linear accelerators, one of which had to be installed in an existing vault and one in a new vault. Since we are in a seismic active area, changes in the local code required us to start placing the new linacs seismically stable. Here, we describe the necessary steps taken to ensure a seismically sound installation of our linacs. For the linac installation to be seismically stable, the linac base frame has to be seismically fixed into the vault floor. The installation of a new linac into an existing vault requires verification of a structurally sound base frame. Knowledge of the previously applied fixation of such is needed and exploratory removal of grouted floor helped in the verification. Understanding the additional load requirements for the locality allows to account for the existing fixation and can potentially reduce the work needed to achieve seismic fixation requirements. For a prospective seismic installation the new linac base frame can be directly installed with the necessary strength. In addition the actual workflow is straight forward and vendor recommendations can be used. In both cases the vendor provided seismic calculations serve as baseline from which a facility should be work from. It is the facilities task to verify the correct installation of a linac in their specific location. An understanding of the seismic landscape can facilitate an appropriate installation at minimal additional cost.

Using failure mode and effects analysis (FMEA) to generate an initial plan check checklist for improved safety in radiation treatment.

PURPOSE: To apply failure mode and effect analysis (FMEA) to generate an effective and efficient initial physics plan checklist. METHODS: A team of physicists, dosimetrists, and therapists was setup to reconstruct the workflow processes involved in the generation of a treatment plan beginning from simulation. The team then identified possible failure modes in each of the processes. For each failure mode, the severity (S), frequency of occurrence (O), and the probability of detection (D) was assigned a value and the risk priority number (RPN) was calculated. The values assigned were based on TG 100. Prior to assigning a value, the team discussed the values in the scoring system to minimize randomness in scoring. A local database of errors was used to help guide the scoring of frequency. RESULTS: Twenty-seven process steps and 50 possible failure modes were identified starting from simulation to the final approved plan ready for treatment at the machine. Any failure mode that scored an average RPN value of 20 or greater was deemed "eligible" to be placed on the second checklist. In addition, any failure mode with a severity score value of 4 or greater was also considered for inclusion in the checklist. As a by-product of this procedure, safety improvement methods such as automation and standardization of certain processes (e.g., dose constraint checking, check tools), removal of manual transcription of treatment-related information as well as staff education were implemented, although this was not the team's original objective. Prior to the implementation of the new FMEA-based checklist, an in-service for all the second checkers was organized to ensure further standardization of the process. CONCLUSION: The FMEA proved to be a valuable tool for identifying vulnerabilities in our workflow and processes in generating a treatment plan and subsequently a new, more effective initial plan checklist was created.

A systematic evaluation of the error detection abilities of a new diode transmission detector.

Transmission detectors meant to measure every beam delivered on a linear accelerator are now becoming available for monitoring the quality of the dose distribution delivered to the patient daily. The purpose of this work is to present results from a systematic evaluation of the error detection capabilities of one such detector, the Delta4 Discover. Existing patient treatment plans were modified through in-house-developed software to mimic various delivery errors that have been observed in the past. Errors included shifts in multileaf collimator leaf positions, changing the beam energy from what was planned, and a simulation of what would happen if the secondary collimator jaws did not track with the leaves as they moved. The study was done for simple 3D plans, static gantry intensity modulated radiation therapy plans as well as dynamic arc and volumetric modulated arc therapy (VMAT) plans. Baseline plans were delivered with both the Discover device and the Delta4 Phantom+ to establish baseline gamma pass rates. Modified plans were then delivered using the Discover only and the predicted change in gamma pass rate, as well as the detected leaf positions were evaluated. Leaf deviations as small as 0.5 mm for a static three-dimensional field were detected, with this detection limit growing to 1 mm with more complex delivery modalities such as VMAT. The gamma pass rates dropped noticeably once the intentional leaf error introduced was greater than the distance-to-agreement criterion. The unit also demonstrated the desired drop in gamma pass rates of at least 20% when jaw tracking was intentionally disabled and when an incorrect energy was used for the delivery. With its ability to find errors intentionally introduced into delivered plans, the Discover shows promise of being a valuable, independent error detection tool that should serve to detect delivery errors that can occur during radiotherapy treatment.

Percent depth-dose distribution discrepancies from very small volume ion chambers.

As very small ion chambers become commercially available, medical physicists may be inclined to use them during the linear accelerator commissioning process to better characterize the beam in steep dose gradient areas. For this work, a total of eight different ion chambers (volumes from 0.007 cc to 0.6 cc) and four different scanning systems were used to scan PDDs at both +300V and -300V biases. We observed a reproducible, significant difference (overresponse with depth) in PDDs acquired when using very small ion chambers, with specific bias/water tank combinations - up to 5% at a depth of 25 cm in water. This difference was not observed when the PDDs were sampled using the ion chamber in static positions in conjunction with an external electrometer. This suggests noise/signal interference produced by the controller box and cable system assemblies, which can become relatively significant for the very small current signals collected by very small ion chambers, especially at depth as the signal level is even further reduced. Based on the results observed here, the use of very small active volume chambers under specific scanning conditions may lead to collection of erroneous data, introducing systematic errors into the treatment planning system. In case the use of such a chamber is required, we recommend determining whether such erroneous effect exists by comparing the scans with those obtained with a larger chamber.

Planning for mARC treatments with the Eclipse treatment planning system.

While modulated arc (mARC) capabilities have been available on Siemens linear accelerators for almost two years now, there was, until recently, only one treatment planning system capable of planning these treatments. The Eclipse treatment planning system now offers a module that can plan for mARC treatments. The purpose of this work was to test the module to determine whether it is capable of creating clinically acceptable plans. A total of 23 plans were created for various clinical sites and all plans delivered without anomaly. The average 3%/3 mm gamma pass rate for the plans was 98.0%, with a standard deviation of 1.7%. For a total of 14 plans, an equivalent static gantry IMRT plan was also created to compare delivery time. In all but two cases, the mARC plans delivered significantly faster than the static gantry plan. We have confirmed the successful creation of mARC plans that are deliverable with high fidelity on an ARTISTE linear accelerator, thus demonstrating the successful implementation of the Eclipse mARC module.

Low dose detection of γ radiation via solvent assisted fluorescence quenching.

Development of low cost, easy-to-use chemical sensor systems for low dose detection of γ radiation remains highly desired for medical radiation therapy and nuclear security monitoring. We report herein on a new fluorescence sensor molecule, 4,4'-di(1H-phenanthro[9,10-d]imidazol-2-yl)biphenyl (DPI-BP), which can be dissolved into halogenated solvents (e.g., CHCl3, CH2Cl2) to enable instant detection of γ radiation down to the 0.01 Gy level. The sensing mechanism is primarily based on radiation induced fluorescence quenching of DPI-BP. Pristine DPI-BP is strongly fluorescent in halogenated solvents. When exposed to γ radiation, the halogenated solvents decompose into various radicals, including hydrogen and chlorine, which then combine to produce hydrochloric acid (HCl). This strong acid interacts with the imidazole group of DPI-BP to convert it into a DPI-BP/HCl adduct. The DPI-BP/HCl adduct possesses a more planar configuration than DPI-BP, enhancing the π-π stacking and thus molecular aggregation. The strong molecular fluorescence of DPI-BP gets quenched upon aggregation, due to the π-π stacking interaction (forming forbidden low-energy excitonic transition). Interestingly the quenched fluorescence can be recovered simply by adding base (e.g., NaOH) into the solution to dissociate the DPI-BP/HCl adduct. Such sensing mechanism was supported by systematic investigations based on HCl titration and dynamic light scattering measurements. To further confirm that the aggregation caused fluorescence quenching, a half size analogue of DPI-BP, 2-phenyl-1H-phenanthro[9,10-d]imidazole (PI-Ph), was synthesized and investigated in comparison with the observations of DPI-BP. PI-Ph shares the same imidazole conjugation structure with DPI-BP and is expected to bind the same way with HCl. However, PI-Ph did not show fluorescence quenching upon binding with HCl likely due to the smaller π-conjugation structure, which can hardly enforce the π-π stacking assembly. Combining the low detection limit, fast and reversible fluorescence quenching response, and low cost of halogenated solvent composites, the sensor system presented may lead to the development of new, simple chemical dosimetry for low dose detection of γ radiation.

Self-expanding stent effects on radiation dosimetry in esophageal cancer.

It is the purpose of this study to evaluate how self-expanding stents (SESs) affect esophageal cancer radiation planning target volumes (PTVs) and dose delivered to surrounding organs at risk (OARs). Ten patients were evaluated, for whom a SES was placed before radiation. A computed tomography (CT) scan obtained before stent placement was fused to the post-stent CT simulation scan. Three methods were used to represent pre-stent PTVs: 1) image fusion (IF), 2) volume approximation (VA), and 3) diameter approximation (DA). PTVs and OARs were contoured per RTOG 1010 protocol using Eclipse Treatment Planning software. Post-stent dosimetry for each patient was compared to approximated pre-stent dosimetry. For each of the three pre-stent approximations (IF, VA, and DA), the mean lung and liver doses and the estimated percentages of lung volumes receiving 5 Gy, 10 Gy, 20 Gy, and 30 Gy, and heart volumes receiving 40 Gy were significantly lower (p-values < 0.02) than those estimated in the post-stent treatment plans. The lung V5, lung V10, and heart V40 constraints were achieved more often using our pre-stent approximations. Esophageal SES placement increases the dose delivered to the lungs, heart, and liver. This may have clinical importance, especially when the dose-volume constraints are near the recommended thresholds, as was the case for lung V5, lung V10, and heart V40. While stents have established benefits for treating patients with significant dysphagia, physicians considering stent placement and radiation therapy must realize the effects stents can have on the dosimetry.

An evaluation of interference of inflatable penile prostheses with electromagnetic localization and tracking system.

PURPOSE: The Calypso system is stated by the manufacturer to be contraindicated for cases where the patient has been implanted with a penile prosthesis. This is due to concern for potential metal interference-related reduction of spatial localization and tracking accuracy. Here we quantify the localization and tracking accuracy of the Calypso system in the presence of inflatable penile prosthesis devices from three most widely used models which account for, essentially, 100% of implants in North America. METHODS: Phantom studies were first performed to quantify the interference of Calypso localization and tracking accuracy from both varying metal (steel) masses, and from the penile prosthetic devices themselves. The interference of varying steel masses was studied as a function of two factors: (a) the mass and (b) the location of steel material. The Calypso daily quality assurance (QA) phantom with three implanted Beacon(®) transponders was used to measure any aliasing of position that might occur due to metal interference. After confirming the safety of use in phantom, we implanted Calypso Beacon(®) transponders in one patient with a previously implanted AMS Model 700 inflatable penile prosthetic device. For each of the 42 delivered treatment fractions, redundant stereotactic ultrasound (US) image guidance was performed to ensure good agreement between US and Calypso guidance. RESULTS: We observed that a steel mass of less than 18 g did not cause any detectable positional aliasing for the Calypso tracking function. The mass of metal material measured to exist in the three penile prosthetic devices studied here (MP35N alloy) was approximately 1 g for each. No positional aliasing was observed for the three prosthetic devices in phantom, and good agreement between redundant US and Calypso was also observed in patient. CONCLUSIONS: Both phantom and patient evaluations with the penile prosthetic devices showed no measurable interference with the Calypso system, thus indicating that accurate Calypso-based alignments can be performed in the presence of current industry standard inflatable penile prosthetic devices.

An Investigation of Radiation Treatment Learning Opportunities in Relation to the Radiation Oncology Electronic Medical Record: A Single Institution Experience.

PURPOSE: A modern radiation oncology electronic medical record (RO-EMR) system represents a sophisticated human-computer interface with the potential to reduce human driven errors and improve patient safety. As the RO-EMR becomes an integral part of clinical processes, it may be advantageous to analyze learning opportunities (LO) based on their relationship with the RO-EMR. This work reviews one institution's documented LO to: (1) study their relationship with the RO-EMR workflow, (2) identify best opportunities to improve RO-EMR workflow design, and (3) identify current RO-EMR workflow challenges. METHODS AND MATERIALS: Internal LO reports for an 11-year contiguous period were categorized by their relationship to the RO-EMR. We also identify the specific components of the RO-EMR used or involved in each LO. Additionally, contributing factor categories from the ASTRO/AAPM sponsored Radiation Oncology Incident Learning System's (RO-ILS) nomenclature was used to characterize LO directly linked to the RO-EMR. RESULTS: A total of 163 LO from the 11-year period were reviewed and analyzed. Most (77.2%) LO involved the RO-EMR in some way. The majority of the LO were the results of human/manual operations. The most common RO-EMR components involved in the studied LO were documentation related to patient setup, treatment session schedule functionality, RO-EMR used as a communication/note-delivery tool, and issues with treatment accessories. Most of the LO had staff lack of attention and policy not followed as 2 of the highest occurring contributing factors. CONCLUSIONS: We found that the majority of LO were related to RO-EMR workflow processes. The high-risk areas were related to manual data entry or manual treatment execution. An evaluation of LO as a function of their relationship with the RO-EMR allowed for opportunities for improvement. In addition to regular radiation oncology quality improvement review and policy update, automated functions in RO-EMR remain highly desirable.

Initial experience and clinical comparison of two image guidance methods for SBRT treatment: 4DCT versus respiratory-triggered imaging.

For Stereotactic Body Radiation Therapy (SBRT) treatment of lung and liver, we quantified the differences between two image guidance methods: 4DCT and ExacTrac respiratory-triggered imaging. Five different patients with five liver lesions and one lung lesion for a total of 19 SBRT delivered fractions were studied. For the 4DCT method, a manual registration process was used between the 4DCT image sets from initial simulation and treatment day to determine the required daily image-guided corrections. We also used the ExacTrac respiratory-triggered imaging capability to verify the target positioning, and calculated the differences in image guidance shifts between these two methods. The mean (standard deviation) of the observed differences in image-guided shifts between 4DCT and ExacTrac respiratory-triggered image guidance was left/right (L/R) = 0.4 (2.0) mm, anterior/posterior (A/P) = 1.4 (1.7) mm, superior/inferior (S/I) = 2.2 (2.0) mm, with no difference larger than 5.0 mm in any given direction for any individual case. The largest error occurred in the S/I direction, with a mean of 2.2 mm for the six lesions. This seems reasonable, because respiratory motion and the resulting imaging uncertainties are most pronounced in this S/I direction. Image guidance shifts derived from ExacTrac triggered imaging at two extreme breathing phases (i.e., full exhale vs. full inhale), agreed well (less than 2.0 mm) with each other. In summary, two very promising image guidance methods of 4DCT and ExacTrac respiratory-triggered imaging were presented and the image guidance shifts were comparable for the patients evaluated in this study.

Evaluation of the dosimetric impact of changes in shoulder position on target coverage for spine SBRT to metastases in the lower cervical spine region.

For patients treated with SBRT for spinal metastases in the cervical area, a thermoplastic mask is the usual immobilization technique. This project investigates the impact of shoulder position variability on target coverage for such cases. Eight HN patients treated in a suite equipped with a CT-on-rails system (CTOR) were randomly chosen. Of these, three were treated with shoulder depressors. For each patient, their planning CT was used to contour spine targets at the C5, C6 and C7 levels for which two VMAT plans were developed to deliver 18 Gy to each target per the RTOG 0631 protocol. One plan used full arcs while the other used avoidance sectors around the lateral positions. For each patient, IGRT CTOR images were used to recalculate doses that would have been delivered from these plans. Target coverage and dose to the spinal cord were compared for four scenarios: full and partial arcs, with or without depressors. A Dunn test showed significant differences between groups with and without shoulder depressors, but not between those with full versus partial arcs. For most of the investigated cases, the coverage ended up being higher than planned due to the shoulder position being inferior at treatment compared to simulation. In some cases, this led to higher spinal cord doses than allowed per protocol. The results of this study confirm that, when treating lower cervical spine lesions with SBRT, special care should be taken to ensure that the shoulders are positioned as they were during planning CT acquisition.

Evaluation of fluence-smoothing feature for three IMRT planning systems.

Commercially available intensity-modulated radiation therapy (IMRT) inverse treatment planning systems (ITPS) typically include a smoothing function which allows the user to vary the complexity of delivered beam fluence patterns. This study evaluated the behavior of three ITPSs when varying smoothing parameters. We evaluated four cases treated with IMRT in our clinic: sinonasal carcinoma (SNC), glioblastoma multiforme (GBM), base of tongue carcinoma (BOT), and prostate carcinoma (PST). Varian Eclipse v6.5, BrainLAB BrainScan v5.31, and Nomos Corvus v6.2 ITPSs were studied for the SNC, GBM, and PST sites. Only Eclipse and Corvus were studied for BOT due to field size constraints of the BrainLAB MM3 collimator. For each ITPS, plans were first optimized using vendor- recommended default "smoothing" values. Treatment plans were then reoptimized, exploring various smoothing values. Key metrics recorded included a delivery complexity (DC) metric and the Ian Paddick Conformality Index (IPCI). Results varied widely by vendor with regard to the impact of smoothing on complexity and conformality. Plans run on the Corvus ITPS showed the logically anticipated increase in DC as smoothing was decreased, along with associated improved organ-at-risk (OAR) sparing. Both Eclipse and BrainScan experienced an expected trend for increased DC as smoothing was decreased. However, this increase did not typically result in appreciably improved OAR sparing. For Eclipse and Corvus, and to a much lesser extent BrainScan, increases in smoothing decreased DC but eventually caused unacceptable losses in plan quality. Depending on the ITPS, potential benefits from optimizing fluence smoothing levels can be significant, allowing for increases in either efficiency or conformality. Because of variability in smoothing function behavior by ITPS, it is important that users familiarize themselves with the effects of varying smoothing parameters for their respective ITPS. Based on experience gained here, we provide recommended workflows for each ITPS to best exploit the fluence-smoothing features of the system.

FMEA-guided transition from microSelectron to Flexitron for HDR brachytherapy.

PURPOSE: To utilize failure mode and effects analysis (FMEA) to effectively direct the transition from the Elekta microSelectron to the Flexitron high dose-rate afterloader system. MATERIALS AND METHODS: Our FMEA was performed in two stages. In the first stage, the lead brachytherapy physicists used FMEA to guide the brainstorming sessions and to identify vulnerabilities during this transition. The second stage of FMEA was carried out 2 months after the clinical release of the Flexitron system. The process map was examined again to further refine and improve the entire process. RESULTS: In the first-stage FMEA, 81 process steps were identified. Moreover, 80 failure modes and their categorized causes were recognized. Checklists and data books containing the corresponding applicator information were verified and updated. Next, based on outcomes of our first-stage FMEA, we chose to implement the commissioning process in two phases. The second stage of FMEA identified error-prone steps in our newly updated processes. This second stage of analysis resulted in the development of new tools and checklist items. CONCLUSIONS: The two-stage FMEA approach successfully directed the transition to the Flexitron system by identifying the necessary changes in the checklists and workflows for all applicators utilized in our clinic. It also led to the decision to use a two-phase commissioning approach. This allowed for minimization clinical downtime, avoidance of an extra source change, and facilitation of efficient staff training. Additionally, multiple project-level failures were discovered. Our experience and outcomes from this FMEA-guided transition should provide valuable information to the brachytherapy community.

Evaluation of dose distribution differences from five algorithms implemented in three commercial treatment planning systems for lung SBRT.

Early stage lung cancer is increasingly being treated using stereotactic body radiation therapy (SBRT). Several advanced treatment planning algorithms are now available in various commercial treatment planning systems. This work compares the dose distributions calculated for the same treatment plan using, five algorithms, in three different treatment planning systems. All plans were normalized to ensure the prescription dose covers 95% of the planning target volume (PTV). Dose to the planning target volume (PTV) was compared using near-minimum dose (D98%), near-maximum dose (D2%) and dose homogeneity, while dose fall-off was compared using D2cm and R50. Dose to the lung was compared using V5Gy, V20Gy and mean lung dose. Statistical analysis shows that dose distributions calculated using Eclipse's Acuros XB and RayStation's Monte Carlo were significantly different from the other dose distributions for the PTV dose parameters investigated. For lung dosimetric parameters, this difference persisted for volumetric modulated arc therapy (VMAT) plans but not for conformal arc plans. While normal tissue complication probability (NTCP) differences were significant for some of the algorithms for VMAT delivery approaches, they were not significantly different for any algorithm for conformal arc plans. All parameters investigated here were within 5% between all algorithms. The results show that, while some small dosimetric differences can be expected around the PTV, the dose distribution to the rest of the treatment area, especially the lungs, should not be clinically-relevant when switching between one of the five algorithms investigated.

Comparison of transperineal ultrasound image guidance technique to transabdominal technique for prostate radiation therapy.

INTRODUCTION: Ultrasound (US) guidance of the prostate has long been conducted using a transabdominal (TA) approach. More recently, a transperineal (TP) approach has been made available for image guidance. Our aim was to determine if both methods produced similar alignments within the same patients. MATERIALS AND METHODS: We utilized two clinical US image guidance (IG) systems (Elekta Clarity and Best BAT). The B-mode Acquisition and Targeting USIG system is a bi-planar, so-called 2.5D USIG system, that is acquired TA. Clarity is a 3D US system that generates a volumetric 3D US data set and US-derived IG contours that are coregistered to the planning CT images. The probe is oriented in the sagittal plane against the perineum (TP). After positioning the patient for treatment using the TP USIG, we maintained the position defined by Clarity tracking and then acquired a TA-based USIG. The two US-based methods of localizing the prostate (TA vs TP) were compared via Bland-Altman (BA) statistical analysis to determine if there was alignment agreement between methods. RESULTS: The BA test for all 101 patients, 2093 fractions resulted in 95% confidence intervals (upper and lower limits of the BA test) of 0.6 mm in LR, 0.9 mm in AP and 1.0 mm in SI. The bias between the two systems was calculated as 0.03, 0.02, and 0.03 mm in LR, AP, and SI. CONCLUSIONS: Both systems resulted in statistically equivalent targeting positions for the prostate. Because of the unique intrafraction, real-time motion tracking capability of the TP system, this solution represents a unique extension to the previously reported clinical benefits of a TA approach by providing assurance of the prostate remaining in the treatment field during beam-on.

Preliminary clinical experience with Calypso anchored beacons for tumor tracking in lung SBRT.

PURPOSE: To present our preliminary experience with the recently released Calypso lung beacons to track lung tumor location during stereotactic body radiation therapy (SBRT). MATERIALS/METHODS: Five recent lung SBRT patients had Calypso lung beacons implanted for tumor tracking during treatment. Beacons were placed by a pulmonologist using fluoroscopic navigation within 1 week prior to planning four-dimensional computed tomography (4DCT) acquisition. Patients were immobilized in a full-body double-vacuum bag. For the first three patients, a verification 4DCT was obtained prior to the first fraction with the patient in the treatment position to assess both beacon migration and motion of tumor and beacons relative to planning day. For each treatment fraction, Calypso was used to position the patient. A verification cone-beam CT (CBCT) confirmed the Calypso-defined target position was appropriate. Real-time Calypso tracking information was also acquired and compared to an action level that was used to determine if the tumor migrated outside of the planning target volume. RESULTS: For four patients, the implant procedure was well tolerated, with average CBCT-based shifts being within 0.2 mm of the shifts reported by Calypso at the time of imaging. The other patient had a small pneumothorax due to very peripheral tumor location and experienced beacon migration. However, the patient quickly recovered from the pneumothorax, and after deactivating that beacon, motion tracking was possible throughout his treatment. CONCLUSIONS: All patients were successfully treated with SBRT using the newly released Calypso lung beacons, with initial positioning confirmed by this clinic's current clinical standard of CBCT. The system allowed us to validate, with real-time confirmation, that the planned internal target volumes were appropriate to each day's extent of actual tumor motion. An efficient and effective workflow for utilizing the new lung beacons for SBRT treatments was developed.

Evaluation of the effects of implementing a diode transmission device into the clinical workflow.

PURPOSE: This work investigated effects of implementing the Delta4 Discover diode transmission detector into the clinical workflow. METHODS: PDD and profile scans were completed with and without the Discover for a number of photon beam energies. Transmission factors were determined for all beam energies and included in Eclipse TPS to account for the attenuation of the Discover. A variety of IMRT plans were delivered to a Delta4 Phantom+ with and without the Discover to evaluate the Discover's effects on IMRT QA. An imaging QA phantom was used to assess the detector's effects on MV image quality. OSLDs placed on the Phantom+ were used to determine the detector's effects on superficial dose. RESULTS: The largest effect on PDDs after dmax was 0.5%. The largest change in beam profile symmetry and flatness was 0.2% and 0.1%, respectively. An average difference in gamma passing rates (2%/2 mm) of 0.2% was observed between plans that did not include the Discover in the measurement and calculation to plans that did include the Discover in the measurement and calculation. The Discover did not significantly change the MV image quality, and the largest observed increase in the relative superficial dose when the Discover was present was 1%. CONCLUSIONS: The effects the Discover has on the linac beam were found to be minimal. The device can be implemented into the clinic without the need to alter the TPS beam modeling, other than accounting for the device's attenuation. However, a careful workflow review to implement the Discover should be completed.

IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119.

AAPM Task Group 119 has produced quantitative confidence limits as baseline expectation values for IMRT commissioning. A set of test cases was developed to assess the overall accuracy of planning and delivery of IMRT treatments. Each test uses contours of targets and avoidance structures drawn within rectangular phantoms. These tests were planned, delivered, measured, and analyzed by nine facilities using a variety of IMRT planning and delivery systems. Each facility had passed the Radiological Physics Center credentialing tests for IMRT. The agreement between the planned and measured doses was determined using ion chamber dosimetry in high and low dose regions, film dosimetry on coronal planes in the phantom with all fields delivered, and planar dosimetry for each field measured perpendicular to the central axis. The planar dose distributions were assessed using gamma criteria of 3%/3 mm. The mean values and standard deviations were used to develop confidence limits for the test results using the concept confidence limit = /mean/ + 1.96sigma. Other facilities can use the test protocol and results as a basis for comparison to this group. Locally derived confidence limits that substantially exceed these baseline values may indicate the need for improved IMRT commissioning.